Risperidone (C007B-258431)

InformationRisperidone (R-64766) is a mutil-targeted antagonist fordopamine, serotonin, adrenergic and histamine receptors, used to treat schizophrenia and bipolar disorder.In vitroRisperidone/xa0binds to both DA and serotonin (5HT) receptors, particularly in the neurons of striatal and limbic structures. Risperidone significantly affects brain nerve growth factor (NGF) level suggesting that it influences the turnover of endogenous growth factors. Risperidone/xa0significantly decreases BDNF concentrations in frontal cortex, occipital cortex and hippocampus and decreases or increases TrkB receptors in selected/xa0brain/xa0structures. Risperidone significantly increases D(2) binding in medial prefrontal cortex/xa0by 34%/xa0in/xa0rat/xa0forebrain/xa0regions. Risperidone produces even greater up-regulation of D(4) receptors in CPu (37%), NAc (32%), and HIP (37%) in/xa0rat/xa0forebrain/xa0regions. Risperidone/xa0significantly inhibits the production of NO and proinflammatory cytokines by activated microglia. Risperidone (1-50 mM) significantly enhances the intracellular accumulation of Rh123 in Caco-2 cells by inhibiting P-gp/xa0activity/xa0with an IC(50) value of 5.87 mM.In vivoRisperidone does not significantly affect bodyweight/xa0gain (BWG), food intake(FI),/xa0glucose/xa0tolerance/xa0or leptin levels, even though prolactin and corticosterone are significantly elevated in male rats. Risperidone significantly increases BWG and FI in female rats. Risperidone (0.05 mg/kg) increases food intake and leptin gene expression in white adipose tissue (WAT), but the rate of/xa0bodyweight/xa0gain/xa0is not affected in rats./xa0Risperidone (0.5 mg/kg) causes a reduction in/xa0bodyweight/xa0gain, as well as enhanced Ucp1 gene expression in BAT and serum prolactin concentrations in rats.Cell Datacell lines：HCT116Concentrations：Incubation Time：Powder Purity:≥99%. Specification: 2mM in DMSO Molecular Formula: C23H27FN4O2 Molecular Weight: 410.48